Nonpenetrating glaucoma surgery cannot achieve lower target IOP

Article

Nonpenetrating glaucoma surgery has little potential to reduce intraocular pressure (IOP) values, according to a study published in the March issue of the Journal of Ophthalmology.

Nonpenetrating glaucoma surgery has little potential to reduce intraocular pressure (IOP) values, according to a study published in the March issue of the Journal of Glaucoma.

Ahmet Hondur, MD of Dinar State Hospital, Turkey and colleagues assessed the impact of nonpenetrating surgery on IOP by reviewing studies on nonpenetrating glaucoma surgery, deep sclerectomy (DS) and viscocanalostomy (VC) (excluding those reporting on combined glaucoma and cataract surgery) from the past five years.

Following primary DS, DS with implant, DS with antimetabolite, primary VC and VC with implant or antimetabolite, cases achieving IOP of ≤21 mmHg were 48.6%, 68.7%, 67.1%, 51.1% and 36.8%, respectively. The research team determined effectiveness in terms of target IOP achievement. For lower set IOP targets, DS and VC success rates were 35 – 86% and 10 – 67%, respectively.

Based on these data, the team concluded that the potential of nonpenetrating surgery to achieve lower target IOPs is low, although this type of surgery can reduce IOP into the high teens.

Recent Videos
David Yorston, FRCS, FRCOphth, discusses his EURETINA keynote lecture
Hoda Shamsnajafabadi, MSc, PhD, presents at the 2024 EURETINA meeting
Timothy L Jackson PhD, MB ChB, FRCOphth, speaks about a combination therapy for VEGF-A/C/D inhibition with sozinibercept and ranibizumab
Carl Awh, MD, FASRS, speaks about the American Society of Retina Specialists (ASRS) at EURETINA
Stefano Mercuri, MD, first author of the winning eposter “Genotype-phenotype correlations in a cohort of genetically determined Retinitis Pigmentosa (RP) Italian patients with Rho gene mutations”
Bahram Bodaghi, MD, PHD, FEBO at the 2024 EURETINA meeting
Enrico Borrelli, MD, FEBO, speaks at EURETINA
Aleksandra Rachitskaya, MD, FASRS, speaks about the Vit-Buckle Society at the 2024 EURETINA Congress.
© 2024 MJH Life Sciences

All rights reserved.